Cargando…
The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma
Metastatic pancreatic adenocarcinoma remains one of the deadliest cancer diagnoses with 5-year survival rates as low as 3%. For decades, gemcitabine remained the mainstay of systemic therapy before the approvals of FOLFIRINOX and gemcitabine with nab-paclitaxel. Despite these advances in the early 2...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720884/ https://www.ncbi.nlm.nih.gov/pubmed/33294843 http://dx.doi.org/10.21037/apc-2020-pda-05 |